Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does BORTEZOMIB Cause Upper respiratory tract infection? 240 Reports in FDA Database

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

According to the FDA Adverse Event Reporting System (FAERS), 240 reports of Upper respiratory tract infection have been filed in association with BORTEZOMIB (bortezomib). This represents 0.5% of all adverse event reports for BORTEZOMIB.

240
Reports of Upper respiratory tract infection with BORTEZOMIB
0.5%
of all BORTEZOMIB reports
43
Deaths
98
Hospitalizations

How Dangerous Is Upper respiratory tract infection From BORTEZOMIB?

Of the 240 reports, 43 (17.9%) resulted in death, 98 (40.8%) required hospitalization, and 18 (7.5%) were considered life-threatening.

Is Upper respiratory tract infection Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for BORTEZOMIB. However, 240 reports have been filed with the FAERS database.

What Other Side Effects Does BORTEZOMIB Cause?

Plasma cell myeloma (6,683) Off label use (4,754) Neuropathy peripheral (4,067) Drug ineffective (2,730) Diarrhoea (2,244) Thrombocytopenia (2,082) Death (2,025) Pneumonia (2,020) Fatigue (1,757) Neutropenia (1,530)

What Other Drugs Cause Upper respiratory tract infection?

ADALIMUMAB (3,306) ETANERCEPT (2,948) TOFACITINIB (1,805) RITUXIMAB (1,713) ABATACEPT (1,623) METHOTREXATE (1,576) TOCILIZUMAB (1,455) APREMILAST (1,437) PREDNISONE (1,354) SECUKINUMAB (1,339)

Which BORTEZOMIB Alternatives Have Lower Upper respiratory tract infection Risk?

BORTEZOMIB vs BOSENTAN BORTEZOMIB vs BOSENTAN\BOSENTAN BORTEZOMIB vs BOSULIF BORTEZOMIB vs BOSUTINIB BORTEZOMIB vs BOTOX

Related Pages

BORTEZOMIB Full Profile All Upper respiratory tract infection Reports All Drugs Causing Upper respiratory tract infection BORTEZOMIB Demographics